Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generic Sofosbuvir and Ribavirin for GT2 HCV
NCT03453346Completed
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sofosbuvir in hepatitis C (HCV), sponsored by Beijing Kawin Technology Share-Holding Co., Ltd. Primary endpoint: Sustained Virologic Response at 12 weeks after end of treatment. Started Aug 2016; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03453346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453346.